Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Modeling Partial and Total Support of Left Ventricular Assist Device for Discrete Hemodynamic Control Framework.

IEEE transactions on bio-medical engineering·2026
Same author

Renal Hemodynamic and Urinary Response to Baroreflex-Mediated Sympathetic Modulation: Insights from High-Resolution Arterial Impedance Analysis in Rats.

American journal of physiology. Regulatory, integrative and comparative physiology·2026
Same author

Positive End-expiratory Pressure Is Associated With Apparent Increases in Single-beat Left-ventricular End-systolic Elastance: Implications of Stroke Volume Sensitivity.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Self-folding graphene scaffolds with integrated electronics for cardiac tissue engineering.

Nanoscale·2026
Same author

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten.

JACC. Case reports·2026
Same author

Automated hemodynamic management system for the prevention of hypotension and cardiac output reduction during general anesthesia: preclinical experimental validation.

Journal of anesthesia·2026

Video Experimental Relacionado

Updated: Jan 14, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Un marco discreto de control hemodinámico: estudio de prueba de concepto para la terapia farmacológica autónoma en la

Yasuyuki Kataoka, Kazunori Uemura, Mitsuji Sampei

    IEEE transactions on bio-medical engineering
    |January 12, 2026
    PubMed
    Resumen

    Este estudio desarrolló un sistema autónomo de terapia farmacológica para la insuficiencia cardíaca aguda (ICA) que estabiliza la hemodinámica y reduce el consumo de oxígeno miocárdico. El marco mejora la precisión del tratamiento y apoya la toma de decisiones clínicas en entornos de cuidados intensivos.

    Palabras clave:
    insuficiencia cardíaca agudaterapia farmacológica autónomacontrol hemodinámicomedicina de cuidados intensivosingeniería de sistemas de control

    Más Videos Relacionados

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
    10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    8.8K
    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
    12:43

    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

    Published on: August 16, 2016

    20.9K

    Videos de Experimentos Relacionados

    Last Updated: Jan 14, 2026

    Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
    07:49

    Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

    Published on: July 21, 2023

    1.9K
    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
    10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    8.8K
    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
    12:43

    Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

    Published on: August 16, 2016

    20.9K

    Área de la Ciencia:

    • Fisiología Cardiovascular
    • Medicina de Cuidados Intensivos
    • Ingeniería de Sistemas de Control

    Sus antecedentes:

    • El manejo de la insuficiencia cardíaca aguda (ICA) presenta desafíos para estabilizar la hemodinámica y minimizar el consumo de oxígeno miocárdico.
    • Las complejas interacciones cardiovasculares exigen estrategias terapéuticas avanzadas para obtener resultados óptimos en los pacientes.

    Objetivo del estudio:

    • Desarrollar un marco discreto de control hemodinámico para la terapia farmacológica autónoma en la ICA.
    • Mejorar la versatilidad del control y el potencial clínico en el manejo de la ICA.
    • Optimizar los objetivos hemodinámicos y minimizar el consumo de oxígeno miocárdico.

    Principales métodos:

    • Se derivó un modelo de dinámica cardiovascular y respuestas a fármacos de múltiples entradas y múltiples salidas.
    • Se diseñó un marco de control óptimo para regular los objetivos hemodinámicos y la administración de fármacos.
    • Se incorporaron restricciones clínicas, incluidos límites de dosis y contraindicaciones.
    • Se validó el rendimiento del control utilizando un simulador cardiovascular.

    Principales resultados:

    • Se logró una regulación hemodinámica multidimensional y se redujo el consumo de oxígeno miocárdico en escenarios simulados de ICA.
    • Se identificaron con éxito casos farmacológicamente intratables evaluando el rango hemodinámico alcanzable.
    • Se demostró un rendimiento estable a pesar de la variabilidad interindividual en las sensibilidades a los fármacos y las propiedades circulatorias.

    Conclusiones:

    • El sistema desarrollado puede servir como una herramienta de asistencia al médico para el manejo de la insuficiencia cardíaca aguda.
    • Proporciona una base para la terapia farmacológica autónoma, mejorando la precisión del tratamiento y reduciendo la carga del personal clínico.
    • Ofrece un enfoque escalable para avanzar en los cuidados intensivos y optimizar la terapia farmacológica en la ICA.